CN111315744A - 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用 - Google Patents

杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用 Download PDF

Info

Publication number
CN111315744A
CN111315744A CN201880072563.8A CN201880072563A CN111315744A CN 111315744 A CN111315744 A CN 111315744A CN 201880072563 A CN201880072563 A CN 201880072563A CN 111315744 A CN111315744 A CN 111315744A
Authority
CN
China
Prior art keywords
heteroaryl
preparation
application
pharmaceutical composition
tetrahydropyridine compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880072563.8A
Other languages
English (en)
Other versions
CN111315744B (zh
Inventor
蔡家强
李桂英
游泽金
孙晓阳
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN111315744A publication Critical patent/CN111315744A/zh
Application granted granted Critical
Publication of CN111315744B publication Critical patent/CN111315744B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了作为乙肝表面抗原(HBsAg)分泌抑制剂的式I的杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用。

Description

PCT国内申请，说明书已公开。

Claims (35)

  1. PCT国内申请，权利要求书已公开。
CN201880072563.8A 2018-01-09 2018-12-25 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用 Active CN111315744B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018100173507 2018-01-09
CN201810017350 2018-01-09
CN2018113292167 2018-11-09
CN201811329216 2018-11-09
PCT/CN2018/123415 WO2019137201A1 (zh) 2018-01-09 2018-12-25 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用

Publications (2)

Publication Number Publication Date
CN111315744A true CN111315744A (zh) 2020-06-19
CN111315744B CN111315744B (zh) 2023-07-14

Family

ID=67219307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072563.8A Active CN111315744B (zh) 2018-01-09 2018-12-25 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用

Country Status (2)

Country Link
CN (1) CN111315744B (zh)
WO (1) WO2019137201A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110857298A (zh) * 2018-08-22 2020-03-03 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、包含其的药物组合物、其制备方法及其用途
CN112142730A (zh) * 2019-06-28 2020-12-29 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物的固体形式及其制备方法
CN115626922A (zh) * 2021-04-29 2023-01-20 苏州恩华生物医药科技有限公司 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-醇衍生物及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177655A1 (en) * 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
CN107108610A (zh) * 2014-12-30 2017-08-29 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
WO2018083081A1 (en) * 2016-11-03 2018-05-11 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108610A (zh) * 2014-12-30 2017-08-29 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
WO2016177655A1 (en) * 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
WO2018083081A1 (en) * 2016-11-03 2018-05-11 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110857298A (zh) * 2018-08-22 2020-03-03 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、包含其的药物组合物、其制备方法及其用途
CN110857298B (zh) * 2018-08-22 2022-05-10 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、包含其的药物组合物、其制备方法及其用途
CN112142730A (zh) * 2019-06-28 2020-12-29 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物的固体形式及其制备方法
CN115626922A (zh) * 2021-04-29 2023-01-20 苏州恩华生物医药科技有限公司 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-醇衍生物及其应用

Also Published As

Publication number Publication date
CN111315744B (zh) 2023-07-14
WO2019137201A1 (zh) 2019-07-18

Similar Documents

Publication Publication Date Title
CN112469713A (zh) 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
CN111757878A (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN114072411A (zh) 作为Wee1抑制剂的嘧啶衍生物
CN114650845A (zh) 抗密蛋白抗体药物偶联物及其医药用途
CN112566907A (zh) 作为ret抑制剂的吡唑衍生物
CN111655682A (zh) 一种高活性sting蛋白激动剂化合物
CN109843873A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
CN111989344A (zh) 用于治疗肿瘤的方法和组合物
CN111511749A (zh) 具有大环分子结构的化合物及其用途
CN112119070A (zh) 选择性jak2抑制剂及其应用
CN114206850A (zh) 作为crac抑制剂的2h-苯并吡喃衍生物
CN109790222A (zh) 抗密蛋白18a2的抗体及其应用
JP2018506302A5 (zh)
CN109641851A (zh) 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
CN109311833A (zh) 二芳基硫醚哌嗪类化合物及其制备方法和用途
CN111868060A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN109641831A (zh) 单体、聚合物、制备方法及其用途
CN111406050A (zh) 吲哚胺2,3-双加氧酶抑制剂及其用途
CN116096713A (zh) 化合物的固体形式
JP2020500907A5 (zh)
CN112313220A (zh) Pd-l1拮抗剂化合物
CN111448185A (zh) 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
CN111247131A (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物
CN111836819A (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
CN111433213A (zh) 作为Akt抑制剂的盐型及其晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant